Welcome to our dedicated page for Pulse Biosciences SEC filings (Ticker: PLSE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pulse Biosciences, Inc. (Nasdaq: PLSE) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries to help interpret complex documents. As a medical device developer focused on bioelectric medicine and nanosecond pulsed field ablation (nsPFA) technology, Pulse Biosciences uses its SEC filings to describe clinical programs, financial performance, governance matters and key milestones for its nPulse platforms.
Investors can review Form 10-K and 10-Q filings for detailed discussions of the company’s business, risk factors, research and development spending and revenue from nPulse capital equipment and Vybrance disposables. Form 8-K current reports highlight material events such as FDA Investigational Device Exemption (IDE) approvals for the NANOCLAMP AF and NANOPULSE-AF atrial fibrillation studies, publication of first-in-human thyroid data, initiation of clinical trials, and quarterly business updates and financial results.
The company’s DEF 14A definitive proxy statement outlines corporate governance, board structure, equity incentive plans and executive compensation policies, providing insight into how management and directors are incentivized as Pulse Biosciences advances its nsPFA technology. Other exhibits and schedules within these filings can include information on stockholder votes, amendments to equity plans and non-GAAP financial measures used by management.
On Stock Titan, each PLSE filing is supplemented with AI-generated explanations that clarify technical language, summarize key sections and point out items such as clinical trial descriptions, regulatory designations and capital structure changes. Users can also monitor Form 4 insider transaction filings when available to see how officers and directors transact in company stock. Together, these tools allow investors, analysts and clinicians to quickly understand the implications of Pulse Biosciences’ SEC filings without reading every line of each document.
Pulse Biosciences Chief Commercial Officer Kevin Patrick Danahy reported a series of option exercises and share sales in Pulse Biosciences, Inc. common stock. On February 9, 10, and 11, 2026, he exercised 20,000 stock options at an exercise price of
On each of those same dates, he then sold 20,000 common shares in open-market transactions at weighted average prices of
Following the reported transactions, Danahy directly holds 365,000 stock options with an exercise price of
A shareholder of Pulse Biosciences (PLSE) has filed a notice to sell 75,000 shares of common stock under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an aggregate market value of $1,556,250 based on the filer’s stated price.
The securities were acquired on 02/09/2026 through a cash exercise of stock options from the issuer, with payment also made on that date. The form indicates no other sales of the issuer’s securities by this person in the past three months.
Pulse Biosciences director Maria Sainz received new stock options in early 2026. On January 8, 2026, she was granted options to buy 50,000 shares of common stock at $14.72 per share. On February 5, 2026, she received options for 3,104 shares at $13.69 per share.
One-third of the 50,000-share grant will vest on the one-year anniversary of the grant, with the rest vesting monthly over the following two years, assuming continued service. The 3,104-share grant will vest in equal installments on March 5, 2026 and June 5, 2026, also conditioned on continued service.
Pulse Biosciences, Inc. director reports no share ownership
Maria Sainz, a director of Pulse Biosciences, Inc., filed an initial Form 3 reflecting her position with the company as of 01/08/2026. The filing states that no non-derivative or derivative securities of Pulse Biosciences are beneficially owned.
Pulse Biosciences, Inc. reported new 6- and 12‑month results from its first‑in‑human feasibility study of the nPulse Cardiac Catheter System for treating atrial fibrillation. In an initial cohort of 150 patients, procedural success was 100% in 75 evaluable patients at 6 months and 96% in 47 evaluable patients at 12 months.
Across 150 treated patients, serious adverse events related to the primary safety endpoint occurred in 1.3% of subjects (2/150). Procedures used an average of 16.1 ± 5.2 applications, with total procedure and fluoroscopy times of 65 ± 28 and 9.8 ± 5.8 minutes, and left atrial dwell time of 21.0 ± 13.3 minutes.
Pulse Biosciences, Inc. furnished a current report describing that on January 14, 2026 it posted an updated investor presentation on its website. The updated deck highlights recent progress in product development programs for its proprietary nPulse Vybrance Percutaneous Electrode, nPulse Cardiac Clamp and nPulse Cardiac Catheter. The company plans to use this presentation in meetings with investors, analysts and others, and has attached it as Exhibit 99.1 and made it available in the Investors section of its website. The information is provided under a Regulation FD disclosure item and is treated as “furnished,” not “filed,” which limits certain legal liabilities.
Pulse Biosciences, Inc. reported that its Board of Directors elected Maria Sainz as a director, effective immediately, and appointed her to the Audit Committee. She will serve until the 2026 annual meeting of stockholders, subject to earlier departure events. Sainz is currently President and Chief Executive Officer of Hyperfine, Inc. and brings over 30 years of healthtech operating experience, including prior CEO roles at AEGEA Medical, CardioKinetix, and Concentric Medical, and board roles at several listed medical technology companies.
Under the company’s non-employee director compensation policy, Sainz is entitled to an annual cash retainer of $55,000 for Board service and $13,000 for Audit Committee service, paid quarterly, with the option to convert some or all of these retainers into stock options. She received an initial option to purchase 50,000 shares of common stock, vesting over three years, and will be eligible for annual options to purchase 30,000 shares at each future annual meeting, vesting over one year, while she remains a director. The company also noted there are no family relationships or related party transactions involving Sainz and disclosed a press release announcing her appointment.
Pulse Biosciences, Inc. reported that the U.S. Food and Drug Administration has approved its Investigational Device Exemption submission, allowing the company to start its NANOPULSE-AF clinical study for treating paroxysmal atrial fibrillation. This single-arm, multicenter, prospective trial will evaluate the primary safety and effectiveness of the company’s nPulse Cardiac Catheter System in patients with recurrent, drug‑resistant, symptomatic paroxysmal atrial fibrillation.
The study is planned to enroll up to 145 patients across as many as 30 sites, including three sites outside the United States. Pulse Biosciences disclosed this update through a press release that is filed as an exhibit and incorporated by reference.
Pulse Biosciences (PLSE) furnished an updated investor presentation as Exhibit 99.1. The deck highlights recent progress across its nPulse Vybrance Percutaneous Electrode, nPulse Cardiac Clamp, and nPulse Cardiac Catheter programs. The company may use the materials in meetings with investors and analysts.
The presentation is available on the company’s website and is treated as “furnished” under Item 7.01, not “filed,” which limits associated Exchange Act liabilities. It contains forward‑looking statements and reflects information as of November 2025.
Pulse Biosciences (PLSE) reported Q3 2025 results. Product revenue was $86 thousand. Operating expenses totaled $20.5 million, driven by research and development of $11.4 million and selling, general and administrative of $8.8 million. The company recorded a net loss of $19.4 million (basic and diluted net loss per share of $0.29).
Cash and cash equivalents were $95.2 million as of September 30, 2025, compared with $118.0 million at year‑end 2024. Net cash used in operating activities was $39.4 million for the nine months ended September 30, 2025. Financing inflows included $14.1 million from warrant exercises, $2.1 million from option exercises, and $0.6 million from the employee stock purchase plan.
The company began capitalizing inventory for the Vybrance Percutaneous Electrode System after FDA 510(k) clearance and commenced the PRECISE BTN clinical trial in September 2025 to support U.S. commercialization, targeting up to 50 patients across up to four sites, with over twenty patients treated to date. Common shares outstanding were 67,738 thousand as of September 30, 2025, and 67,767,578 as of October 31, 2025.
FAQ
What is the current stock price of Pulse Biosciences (PLSE)?
What is the market cap of Pulse Biosciences (PLSE)?
